Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 1/2015

01-03-2015 | Systemic Research (J Cortes, Section Editor)

Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?

Authors: Sathana Dushyanthen, Peter Savas, Karen Willard-Gallo, Carsten Denkert, Roberto Salgado, Sherene Loi

Published in: Current Breast Cancer Reports | Issue 1/2015

Login to get access

Abstract

Breast cancer has not been considered as an immunogenic solid cancer type; however, recent studies demonstrate evidence of significant prognostic information that can be derived from immune cell infiltration via tumour-infiltrating lymphocytes (TILs) in patient tumours. The presence of TILs has been associated with increased response rates to cytotoxic chemotherapy as well as targeted therapies, leading to improved disease-free and overall survival in certain breast cancer subtypes. Accordingly, experts have developed a standardized methodology for evaluating TILs within clinical specimens in histopathological practice. An overview of a newly established practical guideline for TIL evaluation in breast cancer is described in this paper. Furthermore, this review discusses the predictive and prognostic significance of TILs, highlighting recent evidence linking TILs to prognosis in breast cancer. In addition, it summarizes the most current understanding of TIL composition as well as mechanisms of immunity generation and suppression. Overall, the current literature demonstrates that TILs are proving to be a promising target for the treatment of immunogenic breast cancers.
Literature
1.
Liu S et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14(2):R48.CrossRefPubMedCentralPubMed
2.
Ono M et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132(3):793–805.CrossRefPubMed
3.
West NR et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013;108(1):155–62.CrossRefPubMedCentralPubMed
4.
Yamaguchi R et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012;43(10):1688–94.CrossRefPubMed
5.
Sun S et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014;63(4):395–406.CrossRefPubMed
6.
Loi, S., et al., Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Res, 2013. 73: p. abstract S1-05.
7.
Adams S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66.CrossRefPubMed
8.••
Loi S et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–50. This study shows the benefit of TILs in different breast cancer subtypes. It shows an association between higher levels of TILs and decreased distant recurrence rates in primary TNBC as well as increased trastuzumab benefit in HER2+ disease. CrossRefPubMed
9.
Ali HR et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536–43.CrossRefPubMed
10.
Denkert C et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13.CrossRefPubMed
11.
Issa-Nummer Y et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer—a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8(12):e79775.CrossRefPubMedCentralPubMed
12.
Denkert, C., et al., Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66), in SABCS2013: San Antonio, Texas, USA.
13.
Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.CrossRefPubMed
14.
Loi S et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7.CrossRefPubMed
15.
Perez, E.A., et al., Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. J Clin Oncol, 2014. 32: p. abstr 509.
16.
Baselga J et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–61.CrossRefPubMed
17.
Lee S et al. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol. 2013;52(1):73–81.CrossRefPubMed
18.
Seo AN et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705–13.CrossRefPubMedCentralPubMed
19.
Demir L et al. Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. Clin Exp Metastasis. 2013;30(8):1047–62.CrossRefPubMed
20.
Melichar B et al. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res. 2014;34(3):1115–25.PubMed
21.
Koh YW et al. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumour Biol. 2014;35(10):9823–30.CrossRefPubMed
22.
23.
Mohammed ZM et al. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013;109(6):1676–84.CrossRefPubMedCentralPubMed
24.
Schatton T et al. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2014;1102:287–324.CrossRefPubMed
25.
Garcia-Martinez E et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16(6):488.CrossRefPubMedCentralPubMed
26.
Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12(12):1597–611.CrossRefPubMedCentralPubMed
27.
28.
Godet Y et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012;18(10):2943–53.CrossRefPubMed
29.
30.
Rathore AS et al. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res. 2014;140(3):361–9.PubMedCentralPubMed
31.
Song G et al. Elevated level of peripheral CD8(+)CD28(−) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunol Immunother. 2013;62(6):1123–30.CrossRefPubMed
32.
33.
Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70(21):8368–77.CrossRefPubMedCentralPubMed
34.
de Leeuw RJ et al. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18(11):3022–9.CrossRef
35.
Takenaka M et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. 2013;1(4):625–32.PubMedCentralPubMed
36.
Droeser R et al. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer. 2012;12:134.CrossRefPubMedCentralPubMed
37.
Faghih Z et al. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol Lett. 2014;158(1–2):57–65.CrossRefPubMed
38.
39.
Gooden MJ et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.CrossRefPubMedCentralPubMed
40.
Krell J, Frampton AE, Stebbing J. The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter? BMC Cancer. 2012;12:135.CrossRefPubMedCentralPubMed
41.
42.
Cimino-Mathews A et al. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013;44(10):2055–63.CrossRefPubMedCentralPubMed
43.
Kim ST et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol. 2013;36(3):224–31.CrossRefPubMed
44.
Jia Y et al. Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes. Med Oncol. 2014;31(6):981.CrossRefPubMed
45.
Hix LM et al. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem. 2013;288(17):11676–88.CrossRefPubMedCentralPubMed
46.
Boyle ST, Kochetkova M. Breast cancer stem cells and the immune system: promotion, evasion and therapy. J Mammary Gland Biol Neoplasia. 2014;19(2):203–11.CrossRefPubMed
47.
Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15(2):e58–68.CrossRefPubMed
48.
Dong DD et al. Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. Hum Immunol. 2012;73(10):998–1004.CrossRefPubMed
49.
50.
51.
Schirrmacher V et al. T cell memory, anergy and immunotherapy in breast cancer. J Mammary Gland Biol Neoplasia. 2002;7(2):201–8.CrossRefPubMed
52.
Schalper KA. PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer. Oncoimmunology. 2014;3:e29288.CrossRefPubMedCentralPubMed
53.
54.
Mamessier E et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011;71(21):6621–32.CrossRefPubMed
55.
Mamessier E et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609–22.CrossRefPubMedCentralPubMed
56.
da Cunha A, Michelin MA, Murta EF. Pattern response of dendritic cells in the tumor microenvironment and breast cancer. World J Clin Oncol. 2014;5(3):495–502.CrossRefPubMedCentralPubMed
57.
Liu Q et al. Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation. J Biol Chem. 2014;289(16):11522–35.CrossRefPubMed
58.
Kadam CY, Abhang SA. Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer. Clin Chim Acta. 2015;438:98–102.CrossRefPubMed
59.
Bebenek M, Dus D, Kozlak J. Prognostic value of the Fas/Fas ligand system in breast cancer. Contemp Oncol (Pozn). 2013;17(2):120–2.
60.
Holt DM et al. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother. 2012;35(2):179–88.CrossRefPubMedCentralPubMed
61.
Bergenfelz C et al. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J Immunol. 2012;188(11):5448–58.CrossRefPubMed
62.
Gelao L et al. Dendritic cell-based vaccines: clinical applications in breast cancer. Immunotherapy. 2014;6(3):349–60.CrossRefPubMed
63.
Campbell MJ et al. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013;8(10):e79114.CrossRefPubMedCentralPubMed
64.
Deng R et al. Dimethyl sulfoxide suppresses mouse 4T1 breast cancer growth by modulating tumor-associated macrophage differentiation. J Breast Cancer. 2014;17(1):25–32.CrossRefPubMedCentralPubMed
65.
Nickerson NK et al. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncol Res. 2013;20(7):303–17.CrossRefPubMedCentralPubMed
66.
Schalper KA et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773–82.CrossRefPubMed
67.
Kmieciak M et al. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol. 2011;187(2):708–17.CrossRefPubMedCentralPubMed
68.
Wang Z et al. Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk. Tumour Biol. 2014;35(4):3035–9.CrossRefPubMed
69.
Verma C et al. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med. 2013;11:16.CrossRefPubMedCentralPubMed
70.•
Liu S et al. Prognostic significance of FOXP3+ tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16(5):432. This study showed that FOXP3+ regulatory TILs are a poor prognostic indicator in ER-positive breast cancer, but a favorable prognostic factor in the HER2+/ER-negative subtype, thus revealing that the prognostic value of FOXP3+ TILs differs depending on ER and HER2 expression status and CD8+ T cell infiltration. CrossRefPubMedCentralPubMed
71.
Lal A et al. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat. 2013;139(2):381–90.CrossRefPubMed
72.
Forghani P, Khorramizadeh MR, Waller EK. Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. Cancer Med. 2014;3(2):215–24.CrossRefPubMedCentralPubMed
73.
Alizadeh D et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74(1):104–18.CrossRefPubMedCentralPubMed
74.
Yu J et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–97.CrossRefPubMed
75.
76.
77.
Liu H et al. Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK92 cells. Oncol Rep. 2015;33(1):95–102.PubMed
78.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.CrossRefPubMed
79.
80.
81.
82.
Mao H et al. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets. 2010;10(7):728–36.CrossRefPubMed
83.
Jaberipour M et al. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010;16(4):547–51.CrossRefPubMed
84.
Muenst S et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146(1):15–24.CrossRefPubMed
85.
Muenst S et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139(3):667–76.CrossRefPubMed
86.
Gubin MM et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–81.CrossRefPubMed
87.••
Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. This paper reveals that responses to anti-PD-L1 were observed in patients expressing high levels of PD-L1, particularly in TILs. They showed that it was most effective in patients with pre-existing immunity suppressed by PD-L1 and that immunity was reinvigorated on antibody treatment.CrossRefPubMed
88.
Powles T et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.CrossRefPubMed
89.
Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.CrossRefPubMed
90.
Deng L et al. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology. 2014;3:e28499.CrossRefPubMedCentralPubMed
91.
92.
Li F et al. Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate cancer murine model. Neoplasma. 2014;61(6):659–71.CrossRefPubMed
93.
Yoshimoto Y et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One. 2014;9(3):e92572.CrossRefPubMedCentralPubMed
94.••
Kvistborg P et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6(254):254–128. This paper showed that anti-CTLA-4 treatment induces T cell responses and infrequently boosts pre-existing immune responses, providing evidence of anti-CTLA-4 therapy-induced T cell priming as a component of the clinical mode of action.CrossRef
95.
Klyushnenkova EN et al. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Prostate. 2014;74(14):1423–32.CrossRefPubMed
96.
Fourcade J et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res. 2014;74(4):1045–55.CrossRefPubMedCentralPubMed
97.
da Silva IP et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014;2(5):410–22.CrossRefPubMed
98.••
Salgado, R., et al., The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol, 2014. This paper highlights the importance of TIL measurement in breast cancer and provides a detailed standardized methodology for evaluating TILs in histopathological practice, in a research setting as well as in clinical trials.
99.
Salgado R, et al. Harmonization of the evaluation of tumour-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014 Ann Oncol mdu450 first published online September 11, 2014 doi: 10.​1093/​annonc/​mdu450. By permission of Oxford University Press on behalf of the European Society for Medical Oncology
Metadata
Title
Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?
Authors
Sathana Dushyanthen
Peter Savas
Karen Willard-Gallo
Carsten Denkert
Roberto Salgado
Sherene Loi
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 1/2015
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-014-0178-4

Other articles of this Issue 1/2015

Current Breast Cancer Reports 1/2015 Go to the issue

Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Intraoperative Radiotherapy: Is it Ready for Prime Time?

Systemic Research (J Cortes, Section Editor)

Targeting the Tumor Stroma in Breast Cancer

Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Axillary Node Management in Patients Receiving Neoadjuvant Chemotherapy

Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Radiation Treatment Strategies in Patients Undergoing Breast-Conserving Surgery

Systemic Research (J Cortes, Section Editor)

Circulating Tumour Cells as Liquid Biopsy in Breast Cancer—Advancing from Prognostic to Predictive Potential

Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Optimal Margin Width in Breast Conservation Therapy: a Review of the Current Guidelines and Literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits